REPORT DESCRIPTION
Multiple Myeloma Drugs Market – Overview
The increasing microRNA therapeutics, nanomedicine platform emergence, and constant introduction of
effective and safe therapeutics drives the growth of multiple myeloma drugs market. The drugs market is
expected to gain momentum with the addition of monoclonal antibodies and Histone Deacetylase (HDAC)
inhibitors to the current therapeutics array. The biologic therapy of monoclonal antibodies including
DARZALEX and EMPLICITI are largely preferred by the physicians owing to the established clinical
profile. The growing prevalence of the disorder with the surging elderly population, the inefficiency of the
current medication augments to invest in research and development, thereby driving the global market in
the forecast period. Additionally, the supportive treatment demand for restoration procedures including
point of care technologies, approved safety profile and efficiency of monoclonal antibodies is expected to
broaden the drug treatment received by the patients.